Tools & Techniques

CRISPR activation of anti-neoantigen immunity

A Yale team has developed a new use for CRISPR as a cancer vaccine that turns cold tumors hot by boosting neoantigen expression, rather than editing genes. In the realm of cancer, CRISPR’s application to...

Vector rearrangement boosts globin-delivering gene therapies

Through vector genome reorganization, NIH researchers have amplified the manufacturing output and β globin delivery for a lentiviral gene therapy for sickle cell disease and β thalassemia. According to Naoya Uchida, gene therapies delivering β...

Broad takes RNA CRISPR into viral infections

The latest CRISPR study from the Broad Institute takes gene editing into infections caused by RNA viruses, using Cas13 -- which is proving to be one of the most versatile of the CRISPR-Cas enzyme family....

Nobel Prize for cell response to oxygen, a two-sided therapeutic target

Cellular responses to oxygen levels, the focus of this year's Nobel Prize in Physiology or Medicine, are the targets of both inhibiting and activating therapies in clinical development for multiple diseases. William Kaelin, Peter Ratcliffe...

Biotechs propose solutions to impending shortage of AI talent

Competition for AI talent is about to get fierce as companies across biopharma, and every other sector, begin to deploy machine learning in house. Right now, biotechs are aiming to fill their talent needs through...

Locus co-founders open door to new CRISPR systems

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression...

New in vitro multi-organ system offers improved development model, regenerative opportunities

A new way to generate multi-organ systems in the lab could open up options for drug testing models as well as advance the regenerative medicine space. Organoids, miniaturized versions of organs grown in a petri...

Atomwise's JV spree

Drug developers signing up to partner with Atomwise for hit discovery and lead optimization said deal structures made it attractive to take the plunge on the AI company's emerging technology. Last week, Atomwise Inc. announced...

Getting higher-quality hits out of DNA-encoded libraries

DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output. DNA-encoded library...

Enzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands

The first new chemistry for DNA writing in 30 years is gathering steam, with enzymatic synthesis startups developing platforms to generate longer, purer DNA strands in record time. While the new players aim to outperform...

Lasker honors creators of Herceptin

This year’s suite of Lasker Foundation awards includes recognition of the scientists that created anti-HER2 mAb Herceptin trastuzumab, one of the first transformative therapies to come out of biotech, and one that remains standard of...

Gene editing companies say human germline editing ‘currently inappropriate’

Thirteen gene editing companies asserted that human germline gene editing is “currently inappropriate” in a statement released by the Alliance for Regenerative Medicine on Tuesday. The companies cite unresolved “important safety, ethical, legal, and societal...

Digital makes its mark on cognition

Digital biomarkers of cognitive decline could be the antidote to the slop in the subjective tests on which clinical neurology programs often hinge. With proof of concept established in small clinical trials and bigger readouts...

The next frontier for single-cell analysis

With an explosion in scalability, single-cell analysis has begun to invade every aspect of drug development, with early benefits showing themselves in precision targeting. The field’s next challenge is to integrate a wider array of...

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...